Non-vascular stent product classification and domestic manufacturer inventory

Medical Network August 17 Interventional therapy is a new subject that combines imaging diagnosis and clinical treatment. Because it is guided by imaging equipment, the interventional device is introduced into the human lesion through the natural hole or tiny wound of the human body. Treatment, therefore, has the advantages of accuracy, safety, high efficiency, wide indication, less complications, small wounds, and rapid recovery after surgery. It has become the treatment of choice for some diseases and has become the three pillars of clinical practice alongside traditional internal surgery. One of the sexual subjects.

Interventional therapy can be divided into vascular intervention and non-vascular intervention. The main types are as follows:

Currently, because cardiovascular and cerebrovascular diseases have become human health The first killer, therefore, the market for intravascular interventional devices has also developed rapidly with the increasing market demand. Although the application of non-vascular interventional devices in tumor intervention and vertebral body formation has achieved very significant effects, it is concerned. The extent seems to be far worse than heart Intravascular intervention products such as stents.

Among them, non-vascular stents are widely used in the esophagus, intestine, biliary tract, trachea, urethra, etc., for the treatment of respiratory system, digestive tract and urinary system. disease.

According to the 2016-2020 Global Non-Vascular Stent Market Report released by Technavio, a third-party market research organization in the United States, the global non-vascular stent market reached approximately US$ 530 million in 2015. It is expected that this market will be 5.24% by 2020. The compound annual growth rate has grown to $684.1 million, and the market growth rate will increase from 4.88% in 2015 to 5.55% in 2020.

Source: Technavio, 2015

Among them, in 2015, the urethral stent ranked first with 56.08% market share, the digestive tract stent accounted for 39.68%, and the respiratory stent accounted for 4.24%. Among them, the urethral stent included the ureteral stent and the prostate stent, and the digestive tract stent included the esophageal stent. 1. Duodenal stent, colonic stent, biliary stent, pancreatic stent; respiratory stent mainly refers to trachea, bronchial stent or airway stent.

In China, apart from the fact that the more mature coronary stents have been imported into the body, most of the market for interventional devices is still monopolized by several foreign giants. Among them, the main supplier of non-vascular interventions is Boston Scientific, Gram, CRBard and Medtronic.

In China, some leading enterprises involved in the field of minimally invasive devices, such as Minimally Invasive Medicine, Lepu Medical, Xianjian Technology, etc., have focused on cardiovascular intervention, and there is no product layout in non-vascular interventional stents.

According to CFDA data, there are several companies that have approved products for domestic non-vascular stents:

Nanjing Weichuang was established in Nanjing High-tech Zone in 2000. Its main business is endoscopic minimally invasive medical equipment, tumor thermal ablation equipment and consumables, research and development, production and sales of new imaging equipment. Up to now, it has domestic and foreign patents. 86 items, with 56 CFDA product registration certificates in China, including 22 in three categories; CE registration certificate for 31 products and 510 (k) for 9 products in the United States.

In 2015, Nanjing Minimally Invasive Bilateral Biliary Stent Obtained Country medical instruments The registration certificate has made it the first medical device manufacturer approved to produce and sell coated biliary stents in China, breaking the technological monopoly of foreign products in the domestic market.

Changzhou New District Jiasen Medical Stent Device Co., Ltd. is a high-tech specializing in R&D and production of non-vascular medical endoscope stents. enterprise It is also the birthplace of China's first non-vascular stent and China's first non-vascular stent exporter.

On April 28, 2017, Shanghai Aohua Photoelectric Endoscope Co., Ltd. and Changzhou New District Jiasen Medical Stent Device Co., Ltd. signed a strategic cooperation agreement in Shanghai. Changzhou Jiasen Company officially became a member of Aussie Holdings and will be supplemented by Aohua Optoelectronics. Strong product line for endoscopic diagnosis and treatment of high value consumables.

The predecessor of Beijing Weixin Medical is Beijing Longzhou Feidu Memory Alloy Application Research Institute, which is now a holding subsidiary of Shandong Weixin Medical Devices Co., Ltd. Weixin Medical's non-vascular intervention products for the treatment of digestive tract diseases. And the esophageal stent is the main, the 'human body lumen stent' approved in 2016 can also be used for the support of the urethra.